$VASCULAR BIOGENICS LTD(VBLT)$ ASCO2015最大受益者竟是小妖股VBLT，VB-111联合紫杉醇治疗Müllerian cancer的数据不错，57% (8 /14) of the patients had a CA125 response (defined as 50% reduction), 62% (8/13) had clinical benefit (RECIST stable disease) on study. Median progression free survival was 2.0 months (1.6 to 12.0).